Citadel Advisors
BIS icon

Citadel Advisors’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Citadel Advisors’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50
Closed -$1.76K – 14261
2024
Q1 		$1.76K Sell
50
-50
-50% -$1.77K ﹤0.01% 14086
2023
Q4 		$3.61K Hold
100
– – ﹤0.01% 13573
2023
Q3 		$4.48K Sell
100
-100
-50% -$4.21K ﹤0.01% 13481
2023
Q2 		$8.34K Sell
200
-850
-81% -$33.7K ﹤0.01% 13324
2023
Q1 		$42.6K Buy
+1,050
New +$41.8K ﹤0.01% 12367
2019
Q2 		– Sell
-2,200
Closed -$294K – 9167
2019
Q1 		$294K Buy
+2,200
New +$311K ﹤0.01% 7642
2018
Q4 		– Sell
-1,713
Closed -$214K – 9102
2018
Q3 		$214K Buy
1,713
+125
+8% +$16.8K ﹤0.01% 8112
2018
Q2 		$247K Sell
1,588
-437
-22% -$72.7K ﹤0.01% 7542
2018
Q1 		$342K Buy
2,025
+600
+42% +$96.3K ﹤0.01% 6523
2017
Q4 		$251K Buy
+1,425
New +$253K ﹤0.01% 6736
2017
Q2 		– Sell
-1,025
Closed -$228K – 7473
2017
Q1 		$228K Hold
1,025
– – ﹤0.01% 6315
2016
Q4 		$287K Sell
1,025
-250
-20% -$68.4K ﹤0.01% 5740
2016
Q3 		$323K Buy
+1,275
New +$338K ﹤0.01% 5559

Other funds holding BIS

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's BIS Position: Q2 2024 in Review

Citadel Advisors sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q2 2024, closing a stake of 5,325 shares — an estimated $187K sold.

Citadel Advisors first reported a position in BIS in Q4 2014 and held it in 29 quarters. The position peaked at $3.03M in Q3 2015. 6 funds tracked by Wall St. Rank hold BIS as of Q2 2024.

  • Citadel Advisors reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 5,325 ProShares UltraShort NASDAQ Biotechnology shares in Q2 2024, an estimated $187K.
  • Citadel Advisors first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q4 2014 and held it in 29 quarters.
  • Citadel Advisors's ProShares UltraShort NASDAQ Biotechnology position peaked at $3.03M in Q3 2015.
  • 6 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.